Authors David J. Nutt, Lawrence D. Phillips, Michael P. Barnes, Brigitta Brander, Helen Valerie Curran, Alan Fayaz, David P. Finn, Tina Horsted, Julie Moltke, Chloe Sakal, Haggai Sharon, Saoirse E. O’Sullivan, Tim Williams, Gregor Zorn, and Anne K. Schlag Published March 17, 2021 Medical cannabis has been legal in the UK since 2018, but it …
In this update, we reveal the latest data and patient experiences with Project Twenty21, and reveal some exciting news from NICE. We also announce new events related to the project and how you can get involved. Learn more about Project Twenty21 Last month we asked for your stories, and we’re thrilled with the response we …
The Supervised Injection Facility Working Group is a consortium of scientific experts, academics, policy makers, treatment providers and advocacy groups, co-operating to reduce the harms of intravenous drug use.
Drug Science believes that there is good real-world evidence for the positive effects of Supervised Injecting Facilities (SIFs) across the globe.
SIFs are known by many names including Supervised Injection Facilities, Overdose Prevention Centres, and Drug Consumption Rooms. There are subtle nuances between these three amenities, however, their function is to provide safe spaces for people to consume controlled drugs under the supervision of people who can save lives if overdoses occur.
Drug Science believes that access to sterile equipment, overdose prevention and treatment benefits both people who use drugs and the wider community.
Drug Science deems it important to develop the evidence base for reducing drug-related harms by piloting SIFs in the UK. This collaborative initiative will evaluate whether establishing SIFs would; prove to be cost effective, reduce crime, improve public health, lessen drug litter, and increase engagement in treatment services.
The Supervised Injection Facility Working Group (SIFWG) is a consortium of Drug Science experts, leading academics, researchers, people who use drugs, and policy specialists. The SIFWG will work with several partners to establish pilot SIFs for evaluation. Furthermore, the group will inform legal reform and produce recommendations to enable the development of the evidence base on SIFs. In addition to this, it will collate and communicate the evidence base on the role of SIFs in reducing drug-related harm.
Professor of Criminal Justice
Professor of Neuro-psychopharmacology
Chair in Criminology
Professor of Public Health
Professor of Social Policy and Criminal Justice
Editor of the British Journal of General Practice
Reader in Psychology
Consultant Addiction Psychiatrist
Associate Professor in the Sociology of Health
Drug Science Scientific Committee
Advisor, National Drug and Alcohol Treatment Monitoring System
Associate Consultant, IDPC
Deputy Director, Harm Reduction International
Detective Chief Inspector, Thames Valley Police
Head of Partnerships, Transform
Research Associate, Kings College London
Head of Legal Services, Release
Strategy Coordinator, Scottish Drugs Forum
Treatment Provider Representatives
Medical Director, Change Grow Live
Associate Director, With You
Regional Director, Humankind
The Supervised Injection Facility Working Group is supported by treatment providers to ensure that the stakeholders who would be delivering these services are consulted throughout.
In this webinar, Dr Ben Sessa explains how MDMA therapy could treat alcohol use disorder (alcoholism), based on results from his recent safety and tolerability study. He gives background into the psychological trauma which often causes addiction and alcohol use disorder, and how modern psychiatry struggles to treat these conditions at the root cause. He …
By Rayyan Zafar an Honorary Research Assistant for Drug Science Can a ‘double standard’ in paediatric medicine provide a framework to restructure repressive medical cannabis policies? In 2019, a drug called Zolgensma came to market. This drug used a particularly innovative gene therapy technique to treat infants suffering with an extremely rare and catastrophic neuromuscular …
We are greatly encouraged by the news that NICE updated their guidelines around medical cannabis for children with severe epilepsy. The clinical guidance now clearly states: ‘There is no recommendation against the use of cannabis-based medicinal products’ – meaning that Matt and Ali Hughes were able to drop their court case over the prescribing guidelines …